Long COVID, which affects over 44 million Americans, is projected to create an economic burden exceeding $8 billion from 2025 to 2027. This condition arises when COVID-19 symptoms, such as fatigue and shortness of breath, persist for more than three months. Research indicates that between 6% to 20% of individuals who contract COVID-19 may develop long COVID, leading to significant healthcare costs and productivity losses. The estimated annual costs could range from $2.01 billion to $3.4 billion, depending on the prevalence of long COVID cases. The longer symptoms persist, the higher the overall costs, with productivity losses accounting for over 90% of these expenses. Despite the growing crisis, U.S. funding for long COVID research has diminished, including the closure of the Office of Long COVID Research in 2025. The lack of effective treatments and a national strategy to address long COVID further exacerbates the situation, leaving many individuals without adequate support. As the number of long COVID cases continues to rise, the economic implications for society are substantial, emphasizing the urgent need for renewed focus and resources to tackle this ongoing health crisis.